Soma Pharmacy Blognews

FDA Requires New Studies for Movable Spine Supports
WASHINGTON (MedPage Today) — The FDA requested manufacturers of dynamic spine stabilization systems to conduct postmarket surveillance studies to gather data regarding fusion rates and other potential safety hazards.

Depression, Anxiety Linked to Weight Gain
A study that followed British workers for almost two decades found that people with depression, anxiety and other mental health disorders gained more weight over time.

Seasonal Flu Shot Some Help vs. Swine Flu?
A small study of Mexican H1N1 swine flu patients suggests that seasonal flu shots might offer some protection against the new flu. But CDC data finds no hint of such protection.

10 Foods Most Likely to Make You Sick
Some of the healthiest foods, such as leafy greens, may also be the most likely to cause food-borne illness, according to a new report.

Mammograms Cut Risk of Breast Cancer Death
Three-fourths of deaths due to breast cancer occur among women who do not undergo regular screening mammograms, a large study shows.

Aggression in Girls May Be Linked to BPA
New research suggests a link between prenatal exposure to the chemical bisphenol A (BPA) and increased aggression in girls, but not boys, at age 2.

Internet Addiction: Is Your Teen at Risk?
Kids with ADHD, hostility, social phobia, or depression may be more likely to become addicted to the Internet, according to a new study.

Convertibles Hazardous to Your Hearing?
Convertible lovers who take to the open road with the top down may be risking hearing damage, according to a new study out of the U.K.

iMedicor to market Access Pharmaceuticals’ MuGard in North America
ACCESS PHARMACEUTICALS, INC. announced today that it had signed an agreement with iMedicor for the North American commercial launch of MuGard, its FDA approved mucoadhesive oral rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy.

The latest medication to treat schizophrenia "ABILIFY" launched in Canada
A new treatment option for Canadians with schizophrenia, ABILIFY(TM) (aripiprazole), is now available in Canada. For those living with this lifelong disease who may be struggling with a treatment that doesn’t work for them or with side effects that are difficult to tolerate, ABILIFY offers efficacy [...]